Ian E Alexander
Overview
Explore the profile of Ian E Alexander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
2759
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scott S, Westhaus A, Nazareth D, Cabanes-Creus M, Navarro R, Chandra D, et al.
Mol Ther Methods Clin Dev
. 2024 Nov;
32(4):101351.
PMID: 39498467
Gene therapies using recombinant adeno-associated virus (AAV) vectors have demonstrated considerable clinical success in the treatment of genetic disorders. Improved vectors with favorable tropism profiles, decreased immunogenicity, and enhanced manufacturability...
2.
Cunningham S, Zakas P, Sasaki N, van Dijk E, Zhu E, Fu Y, et al.
J Gene Med
. 2024 Aug;
26(8):e3726.
PMID: 39160647
Background: Conventional adeno-associated viral (AAV) vectors, while highly effective in quiescent cells such as hepatocytes in the adult liver, confer less durable transgene expression in proliferating cells owing to episome...
3.
Ginn S, Mandwie M, Alexander I, Edelstein M, Abedi M
J Gene Med
. 2024 Aug;
26(8):e3721.
PMID: 39114903
To date, 3,900 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide. Our database brings together global information on gene therapy clinical activity from trial...
4.
Zakas P, Cunningham S, Doherty A, van Dijk E, Ibraheim R, Yu S, et al.
Mol Ther
. 2024 Jul;
32(10):3356-3371.
PMID: 38981468
Recombinant adeno-associated virus (rAAV) vector gene delivery systems have demonstrated great promise in clinical trials but continue to face durability and dose-related challenges. Unlike rAAV gene therapy, integrating gene addition...
5.
Mietzsch M, Nelson A, Hsi J, Zachary J, Potts L, Chipman P, et al.
bioRxiv
. 2024 May;
PMID: 38746165
Monoclonal antibodies (mAbs) are useful tools to dissect the neutralizing antibody response against the adeno-associated virus (AAV) capsids used as gene therapy delivery vectors. This study structurally characterizes the interactions...
6.
Drouyer M, Chu T, Labit E, Haase F, Navarro R, Nazareth D, et al.
Mol Ther Methods Clin Dev
. 2024 Apr;
32(2):101234.
PMID: 38558569
Gene therapies and associated technologies are transforming biomedical research and enabling novel therapeutic options for patients living with debilitating and incurable genetic disorders. The vector system based on recombinant adeno-associated...
7.
Graves L, van Dijk E, Zhu E, Koyyalamudi S, Wotton T, Sung D, et al.
Mol Ther Methods Clin Dev
. 2024 Apr;
32(2):101232.
PMID: 38558568
Despite the availability of life-saving corticosteroids for 70 years, treatment for adrenal insufficiency is not able to recapitulate physiological diurnal cortisol secretion and results in numerous complications. Gene therapy is...
8.
Ng R, Jian M, Ma O, Xiang A, Bunting M, Kwan J, et al.
J Neuroinflammation
. 2024 Mar;
21(1):77.
PMID: 38539253
Adiponectin (APN) is an adipokine which predominantly expresses in adipocytes with neuroprotective and anti-inflammatory effects. We have recently indicated that circulatory trimeric APN can enter the brain by crossing the...
9.
Cabanes-Creus M, Liao S, Navarro R, Knight M, Nazareth D, Lau N, et al.
Nat Commun
. 2024 Mar;
15(1):1876.
PMID: 38485924
Developing clinically predictive model systems for evaluating gene transfer and gene editing technologies has become increasingly important in the era of personalized medicine. Liver-directed gene therapies present a unique challenge...
10.
Drouyer M, Merjane J, Nazareth D, Knight M, Scott S, Liao S, et al.
Mol Ther
. 2024 Feb;
32(3):818-836.
PMID: 38297833
Directed evolution of natural AAV9 using peptide display libraries have been widely used in the search for an optimal recombinant AAV (rAAV) for transgene delivery across the blood-brain barrier (BBB)...